Access
New
Site

Market Place

A company in the waste management industry based in Canada, is searching for suppliers who can provide technical grade Dopamine. Their forecast-ed annual requirement is 500 Kg.

Reply

A leading Indian pharmaceutical company is searching for 100mg reference standards of Vinorelbine Tartrate and the following products related to their Vinorelbine development -
4-O-Deacetylvinorelbine tartrate, 4-O-deacetylvinorelbine, Leurosine, Catarantine, Anhydro Vinblastine & Vindoline.

Reply

One of the leading generic company in Saudi Arabia with a presence in Gulf markets, Africa and in South East Asia apart from Saudi Arabia, is searching for suppliers of MOQ of Retapamulin with COA and supporting DMF and or CEP. The API will be initially used for developing a new ointment formulation and subsequently for commercialization and thus, in future the quantity required will increase proportionately.

Reply

The first phase of a pharmaceutical project, currently underway in Qatar, will involve the manufacture of Cephalosporin and Penem formulations. Dr. Majid Feddah, the chief consultant on the project will be visiting CPhI Barcelona and is interested in meeting partners who would be open to technology transfer agreements. Interested partners can learn more about the project by viewing its PharmaCompass profile page at the following link - http://www.pharmacompass.com/pharma/party/qatar_pharmaceutical_industries

Reply

An integrated healthcare group functioning in the African region is searching for the following products for the African & CIS regions. The group has more than 20 years of experience in the field, annual revenues in excess of USD 200 million and a presence in more than 20 countries.
Amoxycillin+Clavulanic acid, All commercially available strengths, Oral Solid Dose
Amoxycillin+Clavulanic acid, All commercially available strengths, Oral Suspension
Diclofenac Sodium, 100mg Sustained Release, Oral Solid Dose
Carbamazepine, All commercially available strengths, Oral Solid Dose
Syntometrine, All commercially available strengths, Injectable
Oxytocin, All commercially available strengths, Injectable
Valacyclovir, All commercially available strengths, Oral Solid Dose
Valacyclovir, All commercially available strengths, Topical cream
Valacyclovir, All commercially available strengths, Ointment
All Blood derived products, All commercially available strengths, All
Bupivacaine, All commercially available strengths, Injectable
Atracurium, All commercially available strengths, Injectable
Plasma Volume expanders, All commercially available strengths, Injectable

Reply

A company specialized in research, development and marketing of ophthalmic products in Italy is searching for suppliers who can provide an Olopatadine eye drops dossier that is already registered in the EU.

Reply

Post an enquiry PharmaCompass.com

Our Analysis// RadioCompass

Pfizer won’t split; Mylan CEO draws flak for flying private jet

Pfizer won’t split; Mylan CEO draws flak for flying private jet

This week, Phispers brings you the latest on the EpiPen price-hike controversy, on Amgen’s bi...

Radio Compass

PharmaCompass.com

Assuring integrity in quality systems: A European manufacturer’s perspective

Assuring integrity in quality systems: A European manufacturer’s perspective

Awareness of the top management is key to ensuring integrity, says Roberto Baima, Quality Director a...

Radio Compass

PharmaCompass.com

GSK gets new CEO; Clinical researchers to become more accountable

GSK gets new CEO; Clinical researchers to become more accountable

In global pharma news, GSK finally chose its head of consumer healthcare Emma Walmsley as the CEO to...

Radio Compass

PharmaCompass.com

Mid-2016 Compilation of Non-Compliance Reports issued by U.S. and European Regulators

Mid-2016 Compilation of Non-Compliance Reports issued by U.S. and European Regulators

DMF submissions reveal no slowdown in India & China

DMF submissions reveal no slowdown in India & China

Drugs with no patents and no competition – here’s our list of new ‘price-gouging’ targets

Drugs with no patents and no competition – here’s our list of new ‘price-gouging’ targets

News Library